2-[3-(hydroxymethyl)-4-[(3S)-3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]pyrrolidin-1-yl]phenyl]benzonitrile
C24H20F3N3O2 — CID 156814422
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[3-(hydroxymethyl)-4-[(3S)-3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]pyrrolidin-1-yl]phenyl]benzonitrile
2-[3-(hydroxymethyl)-4-[(3S)-3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]pyrrolidin-1-yl]phenyl]benzonitrile (PubChem CID 156814422) has the molecular formula C24H20F3N3O2 and a molecular weight of 439.44 g/mol. Its IUPAC name is 2-[3-(hydroxymethyl)-4-[(3S)-3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]pyrrolidin-1-yl]phenyl]benzonitrile.
Molecular Properties
| Compound Name | 2-[3-(hydroxymethyl)-4-[(3S)-3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]pyrrolidin-1-yl]phenyl]benzonitrile |
|---|---|
| PubChem CID | 156814422 |
| Molecular Formula | C24H20F3N3O2 |
| Molecular Weight | 439.44 g/mol |
| Exact Mass | 439.15 |
| IUPAC Name | 2-[3-(hydroxymethyl)-4-[(3S)-3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]pyrrolidin-1-yl]phenyl]benzonitrile |
| SMILES | N#Cc1ccccc1-c1ccc(N2CC[C@H](Oc3ccc(C(F)(F)F)cn3)C2)c(CO)c1 |
| InChI | InChI=1S/C24H20F3N3O2/c25-24(26,27)19-6-8-23(29-13-19)32-20-9-10-30(14-20)22-7-5-16(11-18(22)15-31)21-4-2-1-3-17(21)12-28/h1-8,11,13,20,31H,9-10,14-15H2/t20-/m0/s1 |
| InChIKey | HHSSJJQEKIGPGC-FQEVSTJZSA-N |
| XLogP | 4.79 |
| TPSA | 69.38 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 439.44 |
| LogP ≤ 5 | 4.79 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156814422 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.